Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1360-0443.2002.t01-2-00070.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Availability of amyloid modifying therapies will dramatically increase the need for disclosure of Alzheimer's disease (AD) related genetic and/or biomarker test results. The 21st Century Cares Act requires the immediate return of most medical test results, including AD biomarkers. A shortage of genetic counselors and dementia specialists already exists, thus driving the need for scalable methods to responsibly communicate test results.
View Article and Find Full Text PDFBackground: Phase 3 randomized clinical trials within Alzheimer's Disease (AD) typically last over 18 months. Post-baseline participants can use additional treatment for Alzheimer's disease, potentially impacting the cognitive ability as evaluated by the primary endpoint. Consequently, this could overestimate or underestimate the treatment effect, depending on the distribution of usage between treatment arms.
View Article and Find Full Text PDFBackground: Positive findings from testing therapeutics in AD animal models are often not translated to effective treatments due to the poor methodological rigor and inadequate reporting practices of therapeutic efficacy studies. The Alzheimer's Disease Preclinical Efficacy Database (AlzPED), developed by the NIA, is a searchable and publicly available knowledgebase that prioritizes and promotes the use of rigorous methodology to ameliorate this translation gap. Through a checklist of experimental design elements - the Rigor Report Card - AlzPED highlights reporting recommendations and standards while providing a practical tool to help plan rigorous therapeutic studies in animals.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
German Center for Neurodegenerative Diseases e.V. (DZNE), Site Rostock/Greifswald, Greifswald, Germany.
Background: Previous trials reported that collaborative Dementia Care Management (cDCM) could be effective for patients and caregivers and cost-effective for healthcare systems in the short term. However, long-term evidence is lacking. Therefore, the study's objective was to determine the long-term efficacy and cost-effectiveness of cDCM compared with usual care.
View Article and Find Full Text PDFDementia Care Practice.
Alzheimers Dement
December 2024
Beuhler Center for Health Policy and Economics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Background: Drug consultations for the new anti-amyloid therapies for Alzheimer's Disease are currently taking place at the Northwestern Neurobehavior and Memory Clinic with potentially eligible patients and their families. Study aims are to: 1) measure patient and family perception, barriers and concerns of the drug treatment following a formal consultation or informal discussion with a neurologist, and 2) gather data on the patient and family experience with the drug consultation as a method for making an informed decision.
Methods: Participants who are potentially eligible for anti-amyloid therapies and have a drug consultation with their behavioral neurologist will be asked to participate in our study survey.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!